Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US.
Anushka Bhaskar, MPhil
Advertisement
Articles by Anushka Bhaskar, MPhil
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Howard A. “Skip” Burris, III, MD: An Oncology Pioneer Reflects on Patients, Progress, and Purpose
2
New Bill Makes CMS Enforcer in PBM, Pharmacy Relationship: A Q&A With Jesse Dresser, Esq
3
Asundexian Cuts Recurrent Stroke Risk Without More Bleeding: Mukul Sharma, MD, MSc
4
Faricimab Safe, Effective for Use in Treating nAMD in Treatment-Naive Eyes
5